Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This short review is dedicated to Sidney Farber and his Children’s Cancer Research Foundation where, in 1947, carcinochemotherapy was initiated.
Preview
Unable to display preview. Download preview PDF.
References
Adamson, R. H., Fabro, S.: Some studies with asparaginase, asparagine and asparagine analogues. Proc. Amer. Ass. Cancer Res. 9, 2 (3) (1968).
— —Antitumor activity and other biological property of l-asparaginase. A review. Cancer Chemother. Rep. 52, 617–626 (1968).
Alarcon, R. A.: Isolation of acrolein from mixtures of spermine with calf serum and its effects on mammalian cells. Arch. Biochem. 106, 240–242 (1964).
— Acrolein II. Studies on the fluorescence produced by acrolein, spermine and related compounds with resorcinol and calf serum. Arch. Biochem. 113, 281–287 (1966).
— Fluorometric determination of acrolein and related compounds with m-aminophenol. Analyt. Chem. 40, 1704–1708 (1968).
Alexander, P.: Immunotherapy of leukemia. The use of different classes of immune lymphocytes. Cancer Res. 27, 2521–2526 (1967).
— Immunotherapy of cancer. Experiments with primary tumours and syngeneic tumour grafts. In: Progr. Exp. Tumor Res. (Basel) 10, 22–71 (1968a).
— Treatment of experimental tumours with immune lymphocytes. In: Proc. Int. Symp. on Gammapathies, Infections, Cancer and Immunity, p. 81–83 (V. Chini, S. Bonomo and C. Sirtori, eds.), 1968b.
— Hamilton Fairley, G.: Cellular resistance to tumours. Brit. med. Bull. 23, 86–92 (1967).
Anglesio, E.: The treatment of Hodgkin’s disease. In: Recent results in cancer research, vol. 18, p. 30–42. Berlin-Heidelberg-New York: Springer 1969.
Bahnson, C. G.: Chm., Second Conference on Psychophysiological Aspects of Cancer May 1968. Ann. N.Y. Acad. Sci. in press (1969).
Banks, B. E. C., Banthorpe, D. V., Berry, D. V., Davies, H. ff. S., Doonan, S., Lamont, D. M., Shipolini, R., Vernon, C. A.: The preparation of nerve growth factors from snake venoms. Biochem. J. 108, 157–158 (1968).
Bardos, T. J., Gordon, H. L., Chmielewicz, Z. F., Kutz, R. L., Ambrus, J. L.: Screening of animal tissues for inhibitory substances. Abstr. Papers, SO 596, IXth Int. Cancer Congr., Tokyo 1966.
— — — — —Systemic investigations of the presence of growth inhibitory substances in animal tissues. Cancer Res. 28, 1620–1630 (1968).
Barry, V. C., Conalty, M. L., O’Callaghan, C. N., Twomey, D.: Anticancer agents III. Synthesis and anticancer activity of some bisthiosemicarbazones and thiosemicarbazones. Proc. roy. Irish Acad. B 65, 309–324 (1967).
— — McCormick, J. E., McElhinney, R. S., McInerney, M. R., O’sullivan, J. F.: Anticancer agents. I. Structure-activity relationships in a series of oxypolysaccharide-thiosemicarbazide derivatives. Proc. roy. Irish Acad. B 64, 335–354 (1966).
— — — — — — Twomey, D.: The relationship of chemical structure to anti-cancer activity in substituted thiosemicarbazide derivatives of dicarbonyl compounds. Abstr. Papers SO 550, IXth Int. Cancer Congr., Tokyo 1966.
— — O’sullivan, J. F.: Anticancer activity of bisthiosemicarbazones of methylglyoxal. Cancer Res. 26, 2165–2168 (1966).
Bergel, F.: Chemistry of enzymes in cancer. Springfield (Ill.): Ch. C. Thomas 1961.
— Development, possibilities and prospects of alkylating agents in chemotherapy of cancer (ed. P. A. Plattner), p. 21–31. Amsterdam: Elsevier Publ. Co. 1964a.
— Optical stereospecificity of anti-cancer agents. Farmaco 19, 99–109 (1964b).
— Whence and whither chemotherapy. Proc. roy. Instn. 40, 355–374 (1965).
— Zusammenfassung und Ausblick. In: Molekulare Biologie des Malignen Wachstums. Berlin-Heidelberg-New York: Springer 1966a.
— In place of experimental animals. New Scientist, 9th June, 646–647 (1966b).
— Current advances in cancer research. Nursing Times, London, December 1967.
— Harrap, K. R.: Future possibilities for the development of treatments in leukemia. Cancer Res. 25, 1643–1648 (1965).
— — Scott, A. M.: Interaction between carbonyl groups and biologically essential substituents, part IV. An enzyme model system for cysteine desulphydrase. J. chem. Soc. 1101–1112 (1962).
— Johnson, J. M., Wade, R.: Antitumour activity of a series of acetyldipeptide esters containing melphalan, p. 241–245. In: Proc. 6th Europ. Symp., Athens, Pergamon Press., London 1965.
Best, C. H., Taylor, N. B.: The physiological basis of medical practice. 4th ed. London: Baillière, Tindall & Cox 1945.
Boesen, F., Davis, W.: Cytotoxic drugs in the treatment of cancer. London: Edward Arnold 1969.
Boyland, F.: Hormone withdrawal in the treatment of cancer. Cancer Chemother. Rep. 13, 7–8 (1961).
Bratzel, R. P., Ross, R. B., Goodridge, T. H., Huntress, W. T., Flather, M. T., Johnson, D. E.: A survey of alkylating agents. Cancer Chemother. Rep. 26, 1–506 (1963).
British Association for cancer research, Autumn Mtg., Symposium on Aetiological Factors in Lymphomas, Sept. 1968.
— — — — — The Rationale and Assessment of Cancer Chemotherapy, Owen’s Park, Manchester, April 1969.
Brockmann, H.: Die Actinomycine. Fortschr. Chem. org. Naturstoffe 18, 1–54 (1960).
Brockman, R. W.: Resistance to purine antagonists in experimental leukemia systems. Cancer Res. 25, 1596–1607 (1965).
Brookes, P.: Reaction of alkylating agents with nucleic acids. In: Chemotherapy of cancer (P. A. Plattner, ed.), p. 32–43. Amsterdam: Elsevier Publ. Co. 1964.
Broome, J. D.: Evidence that the l-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature (London) 191, 1114 (1961).
— Evidence that l-asparaginase of guinea pig serum is responsible for its antilymphoma effect. J. exp. Med. 118, 99–120, 121–148 (1963).
— Antilymphoma activity of l-asparaginase in vivo; clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J. nat. Cancer Inst. 35, 967–974 (1965).
— Studies on the tumor inhibitory action of l-asparaginase. Abstr. Papers, SO 584, IXth Int. Cancer Congr., Tokyo 1966.
— Mechanism of action of l-asparaginase. Proc. Conf. on l-Asparaginase, New Brunswick, N. J., 14th March 1968a.
— l-asparaginase: The evolution of a new tumor inhibitory agent. N. Y. Acad, Scie., Ser. II, 30, 690–704 (1968b).
— Private Communication 1969. See also l-asparaginase, presented in: Z. B. Papanastassiou, Memorial Symposium on Current Trends in Cancer Chemotherapy. Med. Chem. Group, N. E. Section, Am. Chem. Soc. May 1969.
Bullough, W. S.: Mitotic and functional homeostasis. Cancer Res. 25, 1683–1727 (1965).
— Laurence, E. B.: Epidermal chalone and mitotic control in the Vx 2 epidermal tumour. Nature (Lond.) 220, 134–135 (1968a).
— —Control of mitosis in rabbit Vx 2 epidermal tumour by means of the epidermal chalone. Europ. J. Cancer. 4, 587–594 (1968b).
— —Melanocyte chalone and mitotic control in melanomata. Nature (Lond.) 220, 137–138 (1968c).
— —Control of mitosis in mouse and hamster melanomata by means of melanocyte chalone. Europ. J. Cancer 4, 607–615 (1968d).
Burke, D. C.: Interferon — Some aspects of production and action. In: Symposium on Drugs, Parasites and Hosts (ed. L. G. Goodwin and R. H. Nimmo-Smith), p. 294–319. London: J. & A. Churchill 1962.
Burke, P. F., Lenhard, R. E., Jr., Owens, A. H. Jr.: Therapy for acute leukemia in adults with cytosine arabinoside, vincristine and prednisone. Cancer Chemother. Rep. 52, 305–314 (1968).
Calvert, N., Connors, T. A., Ross, W. C. J.: Aryl-2-halogenalkylamines XXV. Derivatives of sulphonamide designed for selective deposition in neoplastic tissue. J. Europ. J. Cancer 4, 627–636 (1968).
Cannon, W. B.: Organization for physiological homeostasis. Physiol. Rev. 9, 399–431 (1929).
— Wisdom of the body. New York: W. W. Norton 1932.
Carter, S. K.: Streptonigrin. Chemother. Sheet. Nat. Cancer Inst., Nov. 1968.
Clayson, D. B.: Chemical carcinogenesis. Hormones and related compounds, p. 315–371. Hormonal therapy, p. 407. London: J. & A. Churchill, Ltd. 1962.
Cobb, L. M., Connors, T. A., Elson, L. A., Khan, A. H.: 2,4-Dinitro-5-Ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 18, 1519–1527 (1969).
Connors, T. A., Elson, L. A., Haddow, H., Ross, W. C. J.: The pharmacology and tumour growth inhibitory activity of 1-aminocyclopentane-1-carboxylic acid. Biochem. Pharmacol. 5, 108–129 (1960).
— Whisson, M. E.: Cure of mice bearing advanced plasma cell tumours with aniline mustard. Nature (Lond.) 210, 866–867 (1966).
Creighton, A. M., Hellmann, K., Whitecross, S.: Antitumour activity in a series of bisDiketopiperazines. Nature (Lond.) 222, 384–385 (1969).
Davis, W.: Secr., A. Llombart, Hon. Chm. and the Co-ordinating Committee for Human Tumour Investigations. 3rd Int. Symp. on the Biol. Charact. of Hum. Tumrs., Madrid, April 1969.
Day, E. D.: The Immunochemistry of cancer. Amer. Lect. Ser. Springfield (Ill.): Ch. C. Thomas 1965.
De Duve, C.: Lysosomes as targets for drugs. In: the Symposium on the Interaction of Drugs and Subcellular Components in Animal Cells (ed. D. C. Campbell), p. 155–169. London: J. & A. Churchill, Ltd. 1968.
Delorme, E. J., Alexander, P.: Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet 1964II, 117–120.
— Connel, D. I., Mikulska, Z. B., Alexander, P.: Immunological procedures for treating primary chemically induced fibrosarcoma in the rat and a murine-leukemia. In: Symposium on Specific Tumour Antigens (ed. R. J. C. Harris), p. 108–203. U.I.C.C. Monograph No 2, 1967.
De Reuck, A. V. S., Knight, J., eds.: Ciba Foundation Symposium on Cell Differentiation. London: J. & A. Churchill, Ltd. 1967.
Dewys, W. D., Humphreys, S. R., Goldin, A.: Studies on therapeutic effectiveness of drugs, etc. Cancer Chemother. Rep. 52, 229–242 (1968).
Djerassi, I., Farber, S.: Control and prevention of hemorrhage; platelet transfusion. Cancer Res. 25, 1499–1503 (1965).
Druckrey, H., Pressmann, R., Ivankovicz, S., Schmähl, K.: Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z. Krebsforsch. 69, 103–201 (1967).
Elion, G. B., Nathan, H., Bieber, S., Rundles, R. W., Hitchings, G. H.: Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem. Pharmacol. 12, 86–93 (1963). See also Symposium on Allopurinol (ed. J. T. Scott). Ann. rheum. Dis. 25, No 6 (Suppl.), 599–718 (1966).
Elson, L. A., Jarman, M., Ross, W. C. J.: Toxicity, haematological effects and antitumour activity of epoxides derived from disubstituted hexitols. Mode of action of mannitol myleran and dibromomannitol. Europ. J. Cancer 4, 617–625 (1968).
Endicott, K. M.: U.S. strategy against cancer. New Scientist 856–867 (Sept. 1965).
Farber, S.: Clinical and biological studies with actinomycin. In: Amino Acids and Peptides. Ciba Foundation Symposium (eds. G. E. W. Wolstenholme and C. M. O’Connor), p. 138–148. London: J. & A. Churchill Ltd. 1958.
— Remarks during symposium on obstacles to the control of acute leukemia. Cancer Res. 25, 1472 and at closing session (1965).
— Chemotherapy in the treatment of leukemia and Wilm’s tumor. J. Amer. med. Ass. 198, 826–836 (1966).
— Concluding remarks in symposium on acute leukemia and Burkitt’s tumor. Cancer Res. 27, 2658–2660 (1967).
— Mitus, A. T.: Role of actinomycin D (Dactinomycin). Pediatric oncology. In: Actinomycin (ed. S. A. Waksman), p. 137–145. New York: Intersc. Publ. 1968.
Foley, G. E., Barell, E. F., Adams, R. A., Lazarus, H.: Nutritional requirements of human leukemic cells: cystine requirements of diploid cell lines and their heteroploid variants. J. exp. Cell Res. 57, 129–133 (1969).
Fox, B. W.: The sensitivity of Yoshida sarcoma to methylene dimethanesulphonate. Int. J. Cancer 4, 54–60 (1969).
— Jackson, H.: In vivo effects of methylene dimethane sulphonate in proliferating cell systems. Brit. J. Pharmacol. 24, 24–28 (1965).
Freeman, R. G., Knox, J. M.: Treatment of skin cancer. In: Recent results in cancer research, vol. 11, p. 19ff. Berlin-Heidelberg-New York: Springer 1967.
Frei III, E.: Summary of informal discussion on clinical obstacles to the control of acute leukemia. Cancer Res. 25, 1570 (1965).
Frei III, E.: New agents and combination therapy. In: Z. B. Papanastassiou Memorial Symposium on Current Trends in Cancer Chemotherapy. Med. Chem. Group, N. F. Section, Amer. Chem. Soc., May 1969.
French, F. A., Freedlander, B. L.: Chemotherapy studies on transplanted mouse tumors. Cancer Res. 20, 505–538 (1960).
Fullerton, W. W., Boggust, W. A., O’Meara, R. A. Q.: Antithromboplastic activities of fatty acids. J. clin. Path. 20, 624–628 (1967).
Garattini, S., Connors, T. A., Albert, A.: Training course in cancer chemotherapy, Comm. on. Exp. Chemother. of the Comm. on Exptl. Oncol., U.I.C.C. in conj. with Polish Acad. Sciences, Warsaw, Okt. 1968a.
— Amos, D. B., Goldin, A., Milder, J., Rall, D. P., Mandel, H. G.: Conference on the Critical Evaluation of Cancer Chemotherapy. Cherry Hill, New Jersey, April 1969.
— Donelli, M. G., Morasca, L., Rainisio, C., Rosso, R.: Attempts to establish new experimental methods to study antitumural drugs. Acta Genet. med. (Roma) 17, 60–66 (1968b).
Gericke, D.: DL-Glycerinaldehyd eine cytostatische Substanz? Krebsforschungslabor Farbwerke Hoechst. Abstr. 577, Int. Chemother. Kongr. Wien: Med. Acad. 1967.
— Aspekte der Immuntherapy Maligner Tumoren. Med. Klin. 63, 1143–1146 (1968).
— Contzen, H.: Weitere Untersuchungen zur Onkolyse. Abstr. 1081 Int. Chemother. Kongr. Wien: Med. Akad. 1967.
— Engelbert, K.: Onkolysis by Clostridia II. Experiments on a variety of Clostridia in combination with heavy metal. Cancer Res. 24, 217–221, see parts I, III, etc. same volume (1964).
— Schütze. E.: Versuche zur Beeinflussung des Tumorenwachstums durch Mykoplasmen. Zbl. Bakt., I. Abt. Orig. 210, 212–216 (1969).
Gold, P.: Tumor-specific antibody production in digestive system of cancer patients. Symposium on Immunological Aspects of Malignant Disease, 59th Ann. Mtg. Amer. Ass. Cancer Res. Atlantic City, N. J., 12th April 1968.
Goldenberg, I. S., Morin, J. E., Cahow, C. E.: Hormonal therapy for metastatic breast carcinoma in women VII. 6α-chloro-16α-methylpregn-4-ene-3,20-dione. Cancer Chemother. Rep. 50, 327–329 (1966).
Goldin, A., Kaziwara, K., Kinosita, R., Yamamura, Y. (eds.): Cancer Chemotherapy. Jap. Cancer Ass., Gann Monograph 2, Tokyo: Maruzen Co. Ltd. (1967).
— Serpick, A. A., Mantel, N.: Experimental screening procedures and clinical predictability value. Cancer Chemother. Rep. 50, 173–218 (1966).
— Wood, H. B., Jr., Engle, R. R.: Relation of structure of purine and pyrimidine nucleosides to antitumor activity. Cancer Chemother. Rep. (Suppl.) 1, 1–268 (1968).
Gorer, P. A.: Isoantigens of malignant cells. In: Biol. appr. to cancer chemother. (ed. R. C. J. Harris), p. 219–230. London: Academic Press 1961.
Greenwald, E. S.: Cancer chemotherapy. London: Heinemann 1967.
Haddow, A.: Tumour immunology. Brit. med. Bull. 21, 133–139 (1965).
— Alexander, P.: An immunological method of increasing the sensitivity of primary sarcomas to local irradiation with X-rays. Lancet 1964I, 452–457.
Hall, T. C. (in place of S. Farber): Member of the cancer chemotherapy panel. Abstr. of Papers 12, IXth Int. Cancer Congr. Tokyo 1966.
— Kessel, D., Godsill, A., Roberts, D.: Uridine phosphorylation, an overlooked pathway?; 5-fluorouridine, a neglected drug? Proc. Amer. Ass. Cancer Res. 9, 27, 103 (1968).
Hamilton Fairley, G., Simister, J. M., eds.: Cyclophosphamide. Bristol: J. Wright & Sons, Ltd. 1964.
Hancock, P. E. T.: T. Hodgkin. The Fitz Patrick Lecture. J. roy. Coll. Phycns (Lond.) 2, 404–421 (1968).
Handschuhmacher, R. E.: Discussion remark (not recorded) during Symposium of Amer. Cancer Soc., Conference on Obstacles to the Control of Acute Leukemia 1965.
Harrap, K. R., Jackson, R. C.: Some biochemical aspects of leukaemias; leucocyte glutathione metabolism in chronic granulocytic leukemia. Europ. J. Cancer 5, 61–67 (1969).
Harris, R. J. C., ed.: Proc. IXth. Int. Cancer Congr., UICC Monograph Ser. Panel 4. Berlin-Heidelberg-New York: Springer 1967.
Hartmann, J. R., Chm: Clinical study of fluorometholone in acute leukemia in children. Cancer Chemother. Rep. 50, 339–345 (1966).
Heidelberger, C.: Fluorinated pyrimidines — biochemically and clinically useful anti-metabolites. In: Molekulare Biologie des malignen Wachstums, p. 156–176 (Holzer and Holldorf, eds.). Berlin-Heidelberg-New York: Springer 1966.
Hellman, K.: Org., Symposium on Experimental Aspects of Cancer Chemotherapy (tape recordings). Imperial Cancer Res. Fund, London 1968.
Hertz, R., Lewis, J., Lipsett, M. B.: Five years’ experience with chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Amer. J. Obstet. Gynaecol. 82, 631–640 (1961).
Hill, J. M., Roberts, J., Loeb, E., Khan, A., McLellan, A., Hill, R. W.: l-Aspararaginase therapy for leukemia and malignant neoplasms. J. Amer. Med. Assoc. 202, 882–888 (1967).
Hoelzel, F., Hebbelin, H., Hoecke, E., Maas, H.: Die Penetration und die intrazelluläre Verteilung von Trenimon, p-Benzochinon, Actinomycin und TEM bei in vitro-Untersuchungen mit Ehrlich Ascitestumor Zellen. Z. Krebsforsch. 70, 74–94 (1968).
Holzer, H.: Wirkungsmechanismus der Zytostatika. Dtsch. med. J. 12, 312–317 (1961).
— Intrazelluläre Regulation des Stoffwechsels. Naturwissenschaften 50, 260–269 (1963); see also: Diskussion (Leitung: H. Holzer). In: Molekulare Biologie des malignen Wachstums, p. 74–78. Berlin-Heidelberg-New York: Springer 1964.
Hondius Boldingh, W., Laurence, E. B.: Extraction, purification and preliminary characterisation of the epidermal chalone: a tissue specific mitotic inhibitor obtained from vertebrate skin. Europ. J. Biochem. 5, 191 (1968).
Horowitz, B., Madras, B., Meister, A., Old, L. J., Old, E. A.: l-Asparagine synthetase activities of mouse leukemias. Proc. Amer. Ass. Cancer Res. 9, 33, 127 (1968).
Hórvath, I. P., Institoris, L.: Influence of the chemical structure on the biological tendency of cytostatic compounds related to dibromomannitol. Arzneimittel-Forsch. 17, 149–155 (1967).
Howard, J. P., Cevik, N., Murphy, M. L.: Cytosine arabinoside in acute leukemia in children. Cancer Chemother. Rep. 50, 287–291 (1966).
Israel, M., Maddock, C. L., Modest, E. J.: Experimental antitumor activity of synthetic polyamines. Abstr. Papers, SO 555, p. 320. IXth Int. Cancer Congr. Tokyo 1966.
Iversen, O. H.: Chalones of the skin. In: Joint Symposium Ciba Foundation and Wellcome Trust on Homeostatic Regulators, p. 29–56. London: J. & A. Churchill, Ltd. 1969.
Jaques, P. J.: Lysosomes and homeostatic regulation. In: Joint Ciba Foundation and Wellcome Trust Symposium on Homeostatic Regulators (eds. G. E. W. Wolstenholme and J. Knight), p. 180–196. London: J. & A. Churchill, Ltd. 1969.
Jarman, M., Ross, W. C. J.: The formation of epoxides from substituted hexitols. Carbohydr. Res. 9, 1 139–147 (1969a).
— — 4-substituted nicotinic acids and nicotinamides. Pt. II. The preparation of 4-methylnicotinamide riboside. J. chem. Soc. 199–203 (1969b).
Johnson, J. M., Bergel, F.: Biological alkylating agents. In: Hochster and Quastel (eds.), Metabolic inhibitors, vol. II, p. 161–192. New York: Academic Press 1963.
Johnson, R. O., Bisel, H., Andrews, N., Wilson, W., and others: Phase I clinical study of 6α-methylpregn-4-ene-3,11,20-trione. Cancer Chemother. Rep. 50, 671–673 (1966).
Kaung, D. T., Walsh, W. S., Sbar, S., Patno, M. E.: Hydroxyureas in therapy for nonresectable cancer of the lung. Cancer Chemother. Rep. 52, 271–274 (1968).
Keast, D., Grieve, G. M., Stanley, N. F.: Chemotherapy of reovirus-induced murine lymphoma 2731/L. Cancer in Africa 23, 1 (1968).
Kennedy, B. J.: Effect of massive doses of estradiol. undecylate in advanced breast cancer. Cancer Chemother. Rep. 51, 491–495 (1967).
Kessel, D., Hall, T. C., Rosenthal, D.: Uptake and phosphorylation of cytosine arabinoside by normal human blood cells in vitro. Cancer Res. 29, 459–463 (1969).
Klein, E., Farber, S., Djerassi, I.: Control and prevention of hemorrhage; platelet separation. Cancer Res. 25, 1504–1509 (1965).
Klein, G., Sjögren, H. O.: Humoral and cellular factors in homograft and isograft immunity against sarcoma cells. Cancer Res. 20, 452–461 (1960).
— Discussion remark. In: Symposium on Biological Approaches to Cancer Chemotherapy (ed. R. C. J. Harris), p. 230. London: Academic Press 1961a.
— Population changes in drug resistance in tumours. In: Symposium on Biological Approaches to Cancer Chemotherapy (ed. R. C. J. Harris), p. 201–217. London: Academic Press 1961b.
— Humoral and cell-mediated mechanisms for host defense in tumor immunity. In: Viruses inducing Cancer, Implication for Therapy (W. J. Burdett, ed.), p. 323–349. Salt Lake City: Univ. of Utah Press 1966.
— Klein, E., Clifford, P.: Search for host defences in Burkitt lymphoma: Membrane fluorescence tests on biopsies and tissue culture lines. Cancer Res. 27, 2510–2520 (1967).
Kline, I.: Chemotherapy of leukemia L 1210 1-β-D-Arabinofuranosylcytosin Hydrochloride. Cancer Res. 26, 853–859; 1930–1937 (1966).
Koldovsky, P.: Tumor specific transplantation antigen. In: Recent result in cancer research, vol. 22. Berlin-Heidelberg-New York: Springer 1969.
Krakoff, I. H., Clifford, G. O.: Clinical studies of N-hydroxyurethan. Cancer Chemother. Rep. 52, 635–639 (1968).
Larionov, L. F.: Cancer chemotherapy. London and New York: Pergamon Press Ltd., 1965.
Law, L. W.: Presidential address, “Studies of the significance of tumor antigens in the induction and repression of neoplastic diseases”. 59th Ann. Mgt. Amer. Ass. Cancer Res. Cancer Res. 29, 1–22 (1969).
Lawley, P. D.: Mechanism of action of alkylating agents: comparison with other cytotoxic, mutagenic and carcinogenic agents. In: Molekulare Biologie des malignen Wachstums, p. 126–141. See also Diskussion ibid., p. 150–155. Berlin-Heidelberg-New York: Springer 1966.
Lazarus, H., McCoy, T. A., Farber, S., Foley, G. E.: Nutritional requirements of human leukemic cells. Asparagine requirements and the effects of l-asparaginase. J. exp. Cell Res. 57, 134–138 (1969).
Lefkowitz, E., Papac, R. J., Bertino, J. R.: Head and neck cancer. Cancer Chemother. Rep. 51, 305–311 (1967).
Lewerenz, H. J.: Zur Wirkung von DL-Glyceraldehyd auf permanente Kulturen menschlicher Zellen. Z. Krebsforsch. 69, 260–269 (1967).
Li, C. P., Prescott, B., Usdin, F., Eddy, B. E., Martino, E. C.: Local chemotherapy of neoplasm in hamsters with clam extract. Abstr. Papers, SO 583, IXth Int. Cancer congr. Tokyo 1966.
Liss, E., Palme, G., Oeff, K.: In vivo-Versuche über die Wirkung des Trenimons I. Z. Krebsforsch. 71, 89–98 (1968).
Loo, T. L.: Effect of chemotherapy on kinetics of leukemic cells. Cancer Chemother. Rep. 50, 296–297 (1966).
Loveless, A.: Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature (Lond.) 223, 206–207 (1969).
Lovesey, A. C., Ross, W. C. J.: Potential coenzyme inhibitors. Pt. II. Reduction of 4-methylnicotinamide derivatives by sodium dithionate and sodium borohydride. J. chem. Soc. 192–195 (1969).
Maeda, H., Kumagai, K., Ishida, N.: Characterization of neocarcinostatin. J. Antibiot. (Tokyo), Ser. A 19, 253–259 (1966).
Mandel, H. G.: Symposium on critical evaluation of cancer chemotherapy. Bull. Cancer 7, 2 (1969).
Manuila, L., Moles, S., Rentchnick, P. (eds.): New trends in the treatment of cancer. In: Recent results in cancer research, vol. 8. Berlin-Heidelberg-New York: Springer 1967.
Marsden, H. B., Steward, J. K. (eds.): Tumours in children, Wilm’s tumour, p. 225–249. In: Recent results in cancer research, vol. 13. Berlin-Heidelberg-New York: Springer 1968.
Mashburn, L. T., Wriston, J. C.: Tumor-inhibitory effect of l-asparaginase from Escherichia coli. Arch. Biochem. 105, 450–452 (1964).
Mathé, G., ed.: Scientific basis of cancer chemotherapy. In: Recent results in cancer research, vol. 21. Berlin-Heidelberg-New York: Springer 1969a.
— Org. Dir. U. I. C. C., Advanced Course on Tumour Antigens at the Institut de Cancerologie et D’Immunogenétique, Villejuif, France, December 1969b.
— Amiel, J. L., Schwarzenberg, C., Cattan, A., Schneider, M.: Adoptive immunotherapy of acute leukemia, experimental and clinical results. Cancer Res. 25, 1525–1531 (1965).
— Schwarzenberg, L., Amiel, J. L., Schneider, M., Cattan, A., Schlumberger, J. R.: The role of immunology in the treatment of leukemia and hematosarcomas. Cancer Res. 27, 2542–2553 (1967).
Mauger, A. B., Wade, R.: The synthesis of actinomycin analogues. Pt. II. Actinocylgramicidin S. J. Chem. Soc. 1406–1408 (1966).
Meienhofer, J.: A total synthesis of actinomycin. Experientia (Basel) 24, 776–777 (1968).
Mihich, E.: Combined effects of chemotherapy and immunology against leukemia L 1210 DBA/2 mice. Cancer Res. 29, 848–855 (1969).
— Hakala, M. T.: Differences between the antitumor action of 4,4′-Di-acetyl-diphenyl-urea-bis-guanylhydrazone and methylglyoxal-bis-guanylhydrazone. Proc. Amer. Ass. Cancer Res. 9, 48, 190 (1968).
Milder, J. W.: Introductory remarks about symposia in 1964, 1965 and 1967. Cancer Res. 27, 2419 (1967).
Mitchell, J. S. (ed.): The treatment of cancer. Cambridge, Engl.: Cambridge University Press 1965.
Modest, E. J., Foley, G. E., Farber, S.: Polypeptides and proteins as inhibitors. In: Metabolic inhibitors (R. M. Hochster and J. H. Quastel, eds.), p. 75–129. New York and London: Academic Press 1963.
— Sengupta, S. K., Tinter, S. K., Trites, D. H.: Laboratories of Organic Chemistry, Children’s Cancer Res. Found., Boston, Mass.: Private Communication 1969.
Mohr, O., Althoff, J., Kinzel, V., Süss, R., Volm, M.: Melanoma regression induced by “chalone”: a new tumour inhibitory principle acting in vivo. Nature (Lond.) 220, 138–139 (1968).
Monod, J., Changeux, J. P., Jacob, F.: Allosteric proteins and cellular control systems. J. molec. Biol. 6, 306–329 (1963).
Mühlbock, O. (Dir.): Techniques with experimental animals in cancer research. World Health Org. and Int. Agency for Res. on Cancer. Amsterdam, May 1969.
Nass, M. M. K.: Mitochondrial DNA, advances, problems and goals. Science 165, 25–35 (1969).
Nathanson, L., Hall, T. C., Dederick, M. M., Yount, W., Miller, S.: Initial pharmacological studies of three types of combination chemotherapy. Cancer Chemother. Rep. 50, 259–264 (1966).
Nossal, G. J. V.: The impact of immunology on the pediatrics of the future (in press). Rep. Proc. Children’s Hosp. Med. Center, 100th Anniv. Celebr. 1969.
O’Bryan, R. M., Talley, R. W.: Preliminary pharmacology dose-response studies of 7α-methyl-19-nortestosterone in patients. Cancer Chemother. Rep. 50, 335–338 (1966).
Ochoa, M., Jr., Hirschberg, E.: Alkylating agents in experimental chemotherapy, vol. V., pt. 1. New York: Academic Press Inc. 1967.
Oettgen, H. F.: Inhibition of leukemias in man by l-asparaginase. Cancer Res. 26, 2619–2631 (1967).
Ohnuma, T., Bergel, F., Bray, R. C.: Enzymes in cancer: asparaginase from chicken liver. Biochem. J. 103, 238–245 (1966).
Okamoto, H., Shoin, S., Minami, M., Koshimara, S., Shimizu, R.: A Development in the Study of Anticancer Activity of Hemolytic Streptococci, SO 580, Abstr. Papers, IXth Int. Cancer Congr. Tokyo 1966.
Ono, Y., Ito, Y., Maeda, H., Ishida, N.: Mode of action of neocarcinostatin: requirement of protein synthesis for neocarzinostatin-mediated DNA degradation in Sarcina lutea. Biochem. Acta 155, 616–618 (1968).
Papaiannou, A. N., Volk, H.: Massive doses of Δ′-testostololactone for advanced breast cancer. Chemother. 50, 323–326 (1966).
Plattner, P. A. (ed.): Chemotherapy of cancer. Amsterdam: Elsevier Publ. Co. 1964.
Porter, R., Wiltshaw, E. (eds.): Methotrexate in the treatment of cancer. Bristol: J. Wright & Sons, Ltd. 1962.
Pressman, D. (Chm.): Symposium on Immunological Aspects of Malignant Disease. 59th Ann. Mtg. Amer. Ass. Cancer Res., Atlantic City, 12th April 1968.
Rall, D. P., Homan, E. R.: New concepts in cancer chemotherapy. Cancer Chemother. Rep. 51, 247–251 (1967).
Regelson, W.: Antimitotic activity of polyanions. In: Adv. in chemotherap. (A. Goldin, F. Hawking and R. S. Schnitzer, eds.), vol. 3, p. 303–370. New York: Academic Press 1968.
— Holland, J. F., Talley, R. W.: Clinical pharmacological study of kethoxal bis-(thiosemicarbazone) in advanced cancer. Cancer Chemother. Rep. 51, 171–177 (1967).
Roberts, D., Hall, T. C.: Enzyme activity and deoxynucleoside utilization of leukemic leukocytes in relation to drug therapy and resistance. Cancer Res. 29, 166–173 (1969).
Rosenoer, V. M., Whisson, M. E.: A transplantable plasma cell tumour in the study of carcinostatic agents. Biochem. Pharmacol. 13, 589–602 (1964).
Ross, G. T., Stellbach, L., Hertz, L.: Actinomycin D in the treatment of methotrexate-resistant trophoblastic diseases in women. Cancer Res. 22, 1015–1017 (1962).
Ross, W. C. J.: Biological alkylating agents. London: Butterworth 1962.
— Anti-coenzymes. Brit. Emp. Cancer Camp., Ann. Rep. 42, 81 (1964).
— The preparation of some 4-substituted nicotinic acids and nicotinamides. J. chem. Soc. 1816–1821 (1966).
— Some alkylating derivatives of nicotinic acids. J. med. Chem. 10, 257 (1967a).
— Some 6-substituted nicotinamides. Biochem. Pharmacol. 16, 675 (1967b).
— Jarman, M.: Nicotinamide ribosides. Brit. Emp. Cancer Camp., Ann. Rep. 44, 14 (1966); 45, 38 (1967).
Rosso, R., Donelli, M. G., Franchi, G., Garattini, S.: Effect of Triton WR 1339 on cancer dissemination and metastasis. Europ. J. Cancer 5, 77–78 (1969).
Rusconi, A., Fronzo, G. di, Dimarco, A.: Distribution of tritiated daunomycin in normal rats. Cancer Chemother. Rep. 52, 331–337 (1968).
Rytömaa, T., Kiviniemi, K.: Control of cell production in rat chloroleukaemia by means of the granulocytic chalone. Nature (Lond.) 220, 136–138 (1968a).
— —Control of DNA duplication in rat chloroleukaemia by means of the granulocytic chalone. Europ. J. Cancer 4, 595–606 (1968b).
— —Control of granulocyte production. Cell Tissue Kinet. 1, 329–340, 341–350 (1968c).
Sachs, L.: An analysis of the mechanism of carcinogenesis by polyoma virus, hydrocarbons and X-irradiation. In: Molekulare Biologie des malignen Wachstums (Holzer and Holldorf, eds.). Berlin-Heidelberg-New York: Springer 1966.
Sadler, P. W.: Antiviral chemotherapy with isatin-β-thiosemicarbazone and its derivatives. In: Symposium on Drugs, Parasites and Hosts (L. G. Goodwin and R. H. Nimmo-Smith, eds.), p. 286–293. London: J. & A. Churchill, Ltd. 1962.
Sahasrabudhe, M. B.: A new approach to chemotherapy and radiotherapy. J. Sci. Ind. Res. 26, 243–248 (1967).
Sandford, K. K., Earle, W. R., Likely, G. D.: The growth in vitro of single isolated tissue cells. J. nat. Cancer Inst. 9, 229 (1948).
Scanlon, E. T., Hawkins, R. A., Fox, W. W., Smith, W. S.: Fatal homotransplanted melanoma. Cancer (Philad.) 18, 782–794 (1965).
Schmidt, L. H., Fradkin, R., Sullivan, R., Flowers, A.: Comparative pharmacology of alkylating agents. Cancer Chemother. Rep., pts. I, II, and III, Suppl. 2 (Jan. 1965).
Shimkin, M. B. (ed.): Proc. Amer. Ass. Cancer Res. 9, 1–83 (1968).
Simnet, J. D., Fisher, J. M., Heppelstone, A. G.: Tissue specific inhibition of lung alveolar cell mitosis in organ culture. Nature (Lond.) 223, 944–946 (1969).
Skipper, H. E.: The effects of chemotherapy on the kinetics of leukemic cell behaviour. Cancer Res. 25, 1544–1550; Summary of informal discussion on the effects of chemotherapy on the kinetics of leucemic cell behaviour. Cancer Res. 25, 1553–1554 (1965).
— Schabel, F. M., Jr., Wilcox, W. S.: On the criteria and kinetics associated with “curability” of experimental leukemias. Cancer Chemoth. Rep. 35, 3–111 (1964).
Smithers, D. W.: On the nature of neoplasia in man. Edinburgh and London: E. & S. Livingstone 1964.
Southam, C. M.: Evidence of immunological reactions to autochthonous cancer in man. Europ. J. Cancer 1, 173–181 (1965).
— Summary: Immunology of acute leukemia and Burkitt’s tumor. Cancer Res. 27, 2554–2556 (1967).
— Co-existence of allogeneic tumour growth and homograft immunity in man. Europ. J. Cancer 4, 507–511 (1968).
Squibb institute for medical research, New Brunswick, N. J., Proc. of Conference on l-Asparaginase, 14th March 1968.
Stanley, W. M.: Vaccines for viral diseases of children, past, present and future. Rep. Proc. Children’s Hosp. Med. Center. 100th Anniv. Celebr. (in press) 1969.
Stedman’s medical dictionary, 20th ed. London: Baillière, Tindall & Cox 1966.
Stock, J. A.: Antimetabolites. In: Experimental chemotherapy, vol. IV, p. 79–237 (Schnitzer and Hawkings, eds.). New York: Academic Press, Inc. 1966a.
— Antitumour antibiotics. In: Experimental chemotherapy (R. J. Schnitzer and F. Hawking, eds.), vol. IV, p. 241–377. New York: Academic Press, Inc. 1966b.
— Other antitumor agents. In: Experimental chemotherapy, vol. V, pt. II, p. 334–416. New York: Academic Press 1967a.
— Some thoughts on cancer chemotherapy and the future. In: Experimental Chemotherapy, vol. V, pt. II, p. 451–459. New York: Academic Press Inc. 1967b.
Stoker, M.: Regulation of growth and orientation in hamster cells transformed by polyoma virus. Virology 24, 165–174 (1964).
Stoker, M., MacPherson, I.: Studies on transformation of hamster cells by polyoma virus in vitro. Virology 14, 359–370 (1961).
Sugihara, Y., Araki, F.: Carcinostatic substances prepared from bovine liver. Abstr. Papers SO 589, IXth Int. Cancer Congr., Tokyo 1966.
Suguira, K., Brown, G. B.: Antitumor activity of purine N-oxides. Abstr. Paper p. 317 (SO 549). IXth Int. Cancer Congr., Tokyo 1966.
— —Purine N-oxides. XIX. On the oncogenic derivatives of guanine and xanthine and a nononcogenic isomer of xanthine N-oxide. Cancer Res. 27, 925–931 (1967).
Sullivan, M. P. (Chrm.): Symposium on Vincristine. Memphis, Tennessee.. Cancer Chemother. Rep. 52, 453–533 (1968). See also: Antitumural effects of Vinca Rosea alkaloids. In: Proc. 1st Symp. Europ. Chemother. Group, Paris, June 1965. Int. Congr. Ser. No 106 (1965).
Szekerke, M., Wade, R., Bergel, F.: Cytoactive amino acids and peptides. Pt. XIV. Poly-acid copoly-amino acid derivatives of melphalan. J. chem. Soc. 1792–1795 (1968).
Szent Györgyi, A.: Bioelectronics. Science 161, 988–990 (1968).
Tagnon, H. J.: Note. Europ. J. Cancer 4, 507 (1968).
Teller, M., Suguira, K., Parham, J. C., Brown, G. B.: Oncogenicity of purine N-oxide derivatives. Proc. Amer. Ass. Cancer Res. 9, 70 (277) (1968).
Thomas, H. J., Montgomery, J. A.: Complex esters of thioinosinic-(5′) acid. J. med. pharm. Chem. 5, 24–32 (1962).
Timmis, G. M., Williams, D. C.: Chemotherapy of cancer, the antimetabolic approach. London: Butterworths 1967.
Umezawa, H.: The distribution of H-bleomycin in mouse tissue. J. Antibiotics (Tokyo) 21, 638–642 (1968).
Venditti, J. M., Abbott, B. J., Dimarco, A., Goldin, A.: Effectiveness of daunomycin against experimental tumors. Cancer Chemother. Rep. 50, 659–665 (1966).
Vesely, J.: Cancerostatic effects of recently synthesized thymine mustards and their fluoro derivatives. SO 551, Abstr. Papers, IXth Int. Cancer Congr., Tokyo 1966.
Wade, R.: Hormones. In: Experimental Chemotherapy, vol. V, p. 133–331 (Schnitzer and Hawkings, eds.). New York: Academic Press 1967.
— Whisson, M. E., Szekerke, M.: Some serum protein nitrogen mustard complexes with high chemotherapeutic selectivity. Nature (Lond.) 215, 1303–11304 (1967).
Waksman, S. A.: The actinomycetes and their antibiotics. Advanc. appl. Microbiol. 5, 235–315 (1963).
— Furness, F. N.: The actinomycins and their importance in the treatment of tumors in animals and man. Ann. N. Y. Acad. Sci. 89, 283–486 (1960).
Warburg, O.: Über die Ursache des Krebses, p. 1. In: Molekulare Biologie des malignen Wachstums (Holzer and Holldorf, eds.). Berlin-Heidelberg-New York: Springer 1966.
— Gawehn, K., Geissler, A. W., Lorenz, S.: Über die Heilung von Mäuse-Ascites-Krebs durch d-and l-Glycerinaldehyd. Z. klin. Chem. 1, 175–177 (1963).
Weitzel, G. F., Schneider, D., Kummer, D., Ochs, H.: Cytostatischer Wirkungsmechanismus von Natulan. Z. Krebsforsch. 70, 354–365 (1968).
Whisson, M. E.: The interaction of tumour and embryonic tissue in vivo. In: Symposium Ciba Foundation on Cell Differentiation (A. V. S. de Reuck and J. Knight, eds.), p. 219–231. London: J. & A. Churchill, Ltd. 1967.
Wolff, E., Wolff (Mme), E.: Factors of growth and maintenance of tumours as organised structures in vitro. In: Ciba Foundation Symposium on Cell Differentiation (A. V. S. de Reuck and J. Knight, eds.), p. 208–215. London: J. & A. Churchill, Ltd. 1967.
Wolstenholme, G. E. W., Knight, J. (eds.): Homeostatic regulators, Joint Ciba Foundation-Wellcome Trust Symposium, Jan. 1969 (in press). London: J. & A. Churchill, Ltd. 1969.
Woodruff, H. B., Miller, I. M.: Antibiotics in metabolic inhibitors (B. M. Hochster and J. H. Quastel, eds.), vol. II, p. 23–51. New York and London: Academic Press 1963.
Yoshida, T.: org. chrm., Publications IXth Int. Cancer Congr., Tokyo 1966.
Zilber, L. A.: An immunological approach to tumour growth control. In: Symposium on Biological Approaches to Cancer Chemotherapy (R. C. J. Harris, ed.), p. 231–243. London: Academic Press 1961.
Zubrod, C. G.: Quantitative concepts in the clinical study of drugs. In: Advances in Chemotherapy, vol. 1, p. 9–34. New York and London: Academic Press 1964.
— Treatment of the acute leukemias. Cancer Res. 27, 2557–2560 (1967).
— Schepartz, S., Leiter, J., Endicott, K. M., Carrese, L. M., Baker, C. G.: Program of the National Cancer Institute; history, analysis and plans. Cancer Chemother. Rep. 50, 349–540 (1966).
Rights and permissions
Copyright information
© 1970 Springer-Verlag
About this paper
Cite this paper
Bergel, F. (1970). Today’s carcinochemotherapy: Some of its achievements, failures and prospects. In: Reviews of Physiology, Biochemistry and Experimental Pharmacology. Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie, vol 62. Springer, Berlin, Heidelberg. https://doi.org/10.1007/BFb0111423
Download citation
DOI: https://doi.org/10.1007/BFb0111423
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-04811-4
Online ISBN: 978-3-540-36192-3
eBook Packages: Springer Book Archive